Low Testosterone in Senior Men 2026: 9 Warning Signs & TRT Treatment Guide

Low testosterone affects an estimated 30 to 40 percent of men over age 70 — yet the majority are never diagnosed or treated. Testosterone levels in men decline approximately 1 to 2 percent per year after age 30, and by age 70, many men have 30 to 50 percent less testosterone than they had at their peak. This gradual decline, called late-onset hypogonadism (LOH), is not just about sexual function. It affects muscle mass, bone density, mood, energy, and metabolic health in ways that profoundly impact quality of life. Here is what every senior man and his physician needs to know about diagnosing and managing low testosterone in 2026.

Table of Contents

• Understanding Testosterone Decline in Senior Men
• 9 Warning Signs of Low Testosterone
• How Low Testosterone Is Diagnosed
• TRT Treatment Options in 2026
• Benefits and Risks: What the TRAVERSE Trial Revealed
• Natural Ways to Support Testosterone Levels
• Medicare Coverage for Low Testosterone Treatment
• Frequently Asked Questions

Understanding Testosterone Decline in Senior Men

Testosterone is not merely a “sex hormone.” It is an anabolic steroid produced primarily in the testes (with a small contribution from the adrenal glands) that governs muscle protein synthesis, bone mineral density, red blood cell production, cognitive function, and metabolic regulation — among dozens of other physiological roles.

Late-onset hypogonadism (LOH), also called age-related hypogonadism or andropause, is distinct from the abrupt hormonal changes of female menopause. The testosterone decline in men is gradual — roughly 1 to 2 percent per year after age 30 — but the cumulative effect by age 65 to 75 can be significant. Unlike menopause, LOH is not universal; genetic factors, body composition, metabolic health, and lifestyle profoundly influence how quickly and severely testosterone declines.

The clinical threshold for testosterone deficiency (hypogonadism) is a serum total testosterone below 300 ng/dL on two separate morning measurements, according to the American Urological Association 2018 guidelines (reaffirmed 2024). Free testosterone below 9 pg/mL is also diagnostically significant, particularly in men with elevated sex hormone-binding globulin (SHBG), which increases with age and binds testosterone, reducing its bioavailability.

9 Warning Signs of Low Testosterone in Senior Men

The challenge with diagnosing LOH is that its symptoms are nonspecific — fatigue, depression, and cognitive slowing are common in aging for many reasons. The Endocrine Society recommends considering testosterone testing when a man has multiple characteristic symptoms plus a morning total testosterone below 300 ng/dL. The nine most clinically significant warning signs are:

Additional signs include mild anemia (testosterone stimulates erythropoietin production), reduced body and facial hair, loss of morning erections, decreased testicular size, and reduced ejaculatory volume.

How Low Testosterone Is Diagnosed

Diagnosis requires both laboratory confirmation and clinical symptoms — low testosterone alone without symptoms does not warrant treatment per Endocrine Society and AUA guidelines.

Laboratory Workup

Testosterone levels follow a circadian rhythm, peaking between 8 and 10 AM and declining 20 to 25 percent by afternoon. Blood must be drawn in the morning (before 10 AM). Two separate morning total testosterone measurements below 300 ng/dL confirm hypogonadism. Additional tests your physician should order include:

• Free testosterone: Important in seniors where high SHBG reduces bioavailable T
• LH and FSH: Distinguish primary hypogonadism (testicular failure — high LH/FSH) from secondary (hypothalamic-pituitary — low or normal LH/FSH)
• SHBG: Sex hormone-binding globulin; often elevated in elderly men, reducing free T fraction
• PSA (prostate-specific antigen): Baseline required before TRT; repeat at 3 and 6 months after starting
• Hematocrit/CBC: Baseline and monitoring (TRT can raise hematocrit — risk of erythrocytosis)
• Metabolic panel, lipids: Metabolic syndrome both causes and is caused by low T
• Thyroid function (TSH): Hypothyroidism mimics many low T symptoms

Your physician should also screen for sleep apnea (a major cause of secondary hypogonadism), depression (often comorbid), and obesity — all of which independently suppress testosterone and should be addressed regardless of TRT decision.

TRT Treatment Options in 2026

When hypogonadism is confirmed with both biochemical and clinical criteria, testosterone replacement therapy (TRT) is effective at restoring testosterone levels and improving symptoms. Multiple delivery methods are available, each with distinct advantages and considerations for older men:

Benefits and Risks: What the TRAVERSE Trial Revealed

The landmark TRAVERSE Trial (Testosterone Replacement therapy for Assessment of long-term Vascular Events and efficacy ResponSE in hypogonadal men), published in the New England Journal of Medicine in 2023, enrolled 5,204 men aged 45 to 80 with hypogonadism and established cardiovascular disease or elevated CV risk. Key findings after a mean follow-up of 33 months:

• No increase in MACE (major adverse cardiovascular events — heart attack, stroke, CV death): TRT was non-inferior to placebo (HR 0.96, CI 0.78–1.17), resolving a decade-long debate about TRT cardiovascular safety
• 16% lower risk of new-onset Type 2 diabetes in men with prediabetes at baseline (p=0.006)
• Improved bone density: Significant increases in lumbar spine and hip BMD versus placebo
• Small increased risk of atrial fibrillation (3.5% vs 2.4%, p=0.02) and pulmonary embolism (0.9% vs 0.5%, p=0.03) — warrants monitoring in high-risk patients
• Improved sexual function, libido, and energy in symptomatic men

The earlier T-Trials (Testosterone Trials, NEJM 2016) — seven coordinated placebo-controlled trials in 790 men aged 65 and older with total testosterone below 275 ng/dL — confirmed that 1 year of TRT significantly improved sexual function, physical function, bone density, and depressive symptoms in hypogonadal older men.

Absolute contraindications to TRT in seniors: active or high-risk prostate cancer, breast cancer, untreated severe obstructive sleep apnea, erythrocytosis (hematocrit above 54%), severe uncontrolled heart failure, and recent MI or stroke (within 6 months).

Natural Ways to Support Testosterone Levels

For men with borderline-low testosterone or who prefer not to use TRT, evidence-based lifestyle interventions can modestly raise endogenous testosterone and significantly improve the symptoms associated with low T:

• Resistance training 2–3 times per week: The most potent natural testosterone stimulator. Multi-joint compound exercises (squats, deadlifts, rows) with moderate-to-heavy resistance provide the strongest hormonal stimulus. A 12-week resistance training program in older hypogonadal men produced a 15–20% increase in total testosterone in multiple RCTs.
• Optimize sleep (7–9 hours nightly): 60–70% of daily testosterone release occurs during REM and slow-wave sleep. A single week of 5 hours/night sleep reduces testosterone by 10–15%. Treating sleep apnea alone can raise testosterone by 50–100 ng/dL in affected men.
• Lose visceral fat: Adipose tissue converts testosterone to estradiol via aromatase enzyme. Each unit increase in BMI is associated with approximately 2% lower testosterone. A 10% reduction in body weight can raise testosterone 50–100 ng/dL in obese hypogonadal men.
• Zinc: 11 mg/day: Zinc is a cofactor for testosterone synthesis enzymes. Zinc deficiency (common in seniors taking PPIs, thiazide diuretics, or with poor diet) causes a measurable drop in testosterone.
• Vitamin D optimization (40–60 ng/mL): Vitamin D receptors are present in Leydig cells (testosterone-producing cells). A 12-month RCT in men with vitamin D deficiency found a 25% increase in total testosterone with 3,332 IU/day supplementation.
• Reduce alcohol: Even moderate alcohol consumption (3+ drinks/day) suppresses testosterone by inhibiting LH secretion and direct testicular toxicity.

Medicare Coverage for Low Testosterone Treatment

Medicare Part B covers the initial diagnostic evaluation, including testosterone blood tests when medically indicated. Medicare Part D covers FDA-approved TRT formulations, though coverage varies by plan formulary. Injectable testosterone cypionate and enanthate are generally on Tier 1 or Tier 2 formularies at low cost ($10–30/month). Testosterone gels (Androgel, Testim) and patches are typically Tier 3 or Tier 4, requiring prior authorization on many plans and costing $50–150/month after coverage. Pellet implants are generally not covered by Medicare Part D as they involve a minor surgical procedure.

For men on Medicare Advantage plans, prior authorization for TRT is common. Bring your two diagnostic testosterone results plus clinical documentation of symptoms to any prior authorization appeal — the Endocrine Society guidelines explicitly support TRT in symptomatic men with confirmed biochemical hypogonadism, which provides strong grounds for appeal if denied.

What is a “normal” testosterone level for a man over 70?

Reference ranges for total testosterone are typically 300–1,000 ng/dL across all adult men, but aging naturally shifts levels lower. The AUA recommends treatment when total testosterone is consistently below 300 ng/dL in a symptomatic man, regardless of age. Some laboratories use age-adjusted reference ranges that show “normal” lower limits of 200–250 ng/dL for men over 70 — but clinical guidelines focus on symptoms plus biochemistry, not age-adjusted normals alone.

Does testosterone replacement cause prostate cancer?

Decades of research, including the large TRAVERSE Trial (2023), have not demonstrated that TRT causes prostate cancer in men without pre-existing disease. The historical concern arose from observations that testosterone fuels existing prostate cancers. Current guidelines require PSA measurement at baseline and at 3 and 6 months after starting TRT, with urological referral for a PSA rise above 1.4 ng/mL within 12 months or a single PSA above 4 ng/mL. Active prostate cancer remains an absolute contraindication to TRT.

How long before TRT shows results?

Different benefits emerge on different timelines. Libido and mood often improve within 3 to 6 weeks. Sexual function and energy typically improve by 3 months. Muscle mass and strength gains require 3 to 6 months of consistent TRT combined with resistance training. Bone density improvements are measurable at 12 to 24 months. Body composition (fat reduction) generally requires 6 to 12 months. If no clinical improvement is seen after 6 months of confirmed therapeutic testosterone levels, the diagnosis should be reconsidered.

Can I stop TRT once I start?

Yes, but expect your testosterone levels to return to pre-treatment baseline within weeks to months, with return of symptoms. Long-term TRT can also suppress the hypothalamic-pituitary-gonadal (HPG) axis, temporarily reducing the testes’ ability to produce testosterone independently. Stopping TRT abruptly is generally safe but may cause symptom recurrence. Discuss a structured tapering plan with your physician if stopping is desired.

Sources

• TRAVERSE Trial — NEJM 2023: Testosterone Replacement in Hypogonadal Men
• Testosterone Trials (T-Trials) — NEJM 2016
• Endocrine Society Clinical Practice Guidelines — Testosterone Therapy 2018 (Updated 2024)

Related Articles You May Find Helpful

• Sarcopenia and Strength Training for Seniors 2026
• Sleep Apnea in Seniors 2026: 7 Warning Signs & Medicare Treatments
• Osteoporosis Prevention for Seniors 2026
• Best Diet for Seniors Over 70 to Lose Belly Fat
• Senior Health Conditions Guide 2026